OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Indexing: DOAJ-Directory of Open Access Journals.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 6 days from acceptance to publication (median values for papers published in this journal in the first half of 2020, 1-2 days of FREE language polishing time is also included in this period). A first decision provided to authors of manuscripts submitted to this journal are approximately 3.3 weeks (median values) after submission.
Genetics and Epigenetics of Aging
Submission Deadline: October 15, 2020 (Open) Submit Now
Shin Murakami, PhD, FGSA
Professor, Department of Basic Sciences, College of Osteopathic Medicine, Touro University California, 1310 Club Drive, Mare Island, Vallejo, CA 94592, USA
Tel: (707) 638-5903
Fax: (707) 638-5255
Research interests: Aging; stress resistance; cognitive functions; Alzheimer’s disease; genetics; geriatrics; genetics and epigenetics of aging; role of metabolism genes in AMI (age-related memory impairment) and dementia; midlife crisis theory of aging
About This Topic
Welcome to the special issue! Recent advancement of genetic and epigenetic studies opens a new door to the understanding of aging. Human genome project has shifted from the public project to personal genome projects that produce results readily available to the consumer. This trend of direct-to-consumer (DTC) is expected to revolutionize the whole picture of medicine. Studies of aging have been shifting from the understanding the mechanisms of single-gene mutations to that of genetic and epigenetic variations. The variations presumably result in the diversity of longevity at individual levels. The genetic and epigenetic implications must be validated that will be a significant limit for human studies. The model systems are advantageous for functional analysis. The scope of this special issue includes but not limited to the studies of model systems, readily applicable implications to each individual, such as genetic variations and risk assessments, nutritional and pharmacological implications, and age-related diseases and damage (e.g., oxidative stress and age-related glycations) and theories. I hope to extend the invitation to collect a heritable knowledge toward the transition from young to old, which is explained by the middle-life crisis theory of aging.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.